Latest Torcetrapib Stories
Novel Emerging Therapies Are Expected to Reinvigorate a Market Constrained By Patent Expirations of Leading Treatments, According to Findings from Decision Resources Group BURLINGTON, Mass.,
Reportbuyer.com just published a new market research report:
High-density lipoprotein, otherwise known as HDL, was thought to be “good” cholesterol. However, a new study, based on databases of genetic information, disproves the HDL theory and states that rising HDL may not have any change to heart disease risk.
Researchers at Cleveland Clinic reported today that administration of a new drug– evacetrapib – can dramatically increase HDL (good) cholesterol, while significantly lowering LDL (bad) cholesterol).
Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels.
US regulators will be considering a plan from pharmaceutical giant Pfizer to introduce an over-the-counter version of its top-selling heart drug Lipitor.
A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to this study.
- The act of sweetening by admixture of some saccharine substance.